New England Journal of Medicine, Volume 394, Issue 16: Page 1649-1650, April 23, 2026

On April 23, 2026, The New England Journal of Medicine published a brief analysis titled “Same Pill, Different Impact — Reassessing the Efficacy of Nirmatrelvir–Ritonavir” in Volume 394, Issue 16, pages 1649-1650. The piece re-examines the real-world effectiveness of the antiviral combination nirmatrelvir–ritonavir (Paxlovid) in treating COVID-19 among higher-risk populations, noting that while the drug remains a key therapeutic option, its impact varies significantly across patient groups and clinical settings.

The analysis draws on observational data and clinical outcomes from multiple health systems since the drug’s widespread use began in 2022. It highlights that although nirmatrelvir–ritonavir continues to reduce hospitalization and death in certain high-risk patients — particularly those who are immunocompromised, unvaccinated, or have multiple comorbidities — its benefit is less pronounced in vaccinated individuals with mild symptoms or those who receive treatment late in the course of illness.

Researchers emphasize that timing of administration remains critical, with the greatest benefit observed when treatment is initiated within five days of symptom onset. Delays beyond this window are associated with diminished antiviral effect, likely due to advanced viral replication and host inflammatory responses that are less responsive to antiviral intervention.

The analysis also notes emerging patterns of viral rebound in a subset of patients following completion of the five-day treatment course, though these episodes are typically mild and do not consistently lead to worsened clinical outcomes. The journal states that the clinical significance of rebound remains under investigation, with ongoing studies assessing whether extended or retreatment regimens might be warranted in specific cases.

In discussing public health implications, the authors caution against overgeneralizing the drug’s efficacy across all populations. They advocate for continued risk-stratified prescribing guidelines that prioritize nirmatrelvir–ritonavir for patients most likely to benefit, while considering alternative antivirals or supportive care for others based on vaccination status, symptom severity, and underlying health conditions.

The piece concludes by calling for improved real-world surveillance systems to better track treatment outcomes, viral variants, and drug resistance patterns. It stresses that as SARS-CoV-2 continues to evolve, ongoing evaluation of existing therapeutics is essential to ensure that public health strategies remain aligned with the latest evidence.